Moreover, subsequent data from clinical trials of other anti-EpCAM antibody-based drug candidates, such as Edrecolomab [9] and Adecatumumab (MT201) [10, 22], suggested that anti-EpCAM monoclonal antibodies have only limited anti-tumor effects, primarily through activation of complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) [22, 23]. The gene discussed is EPCAM; the disease is neoplasm.